This Phase 2a proof of concept (PoC) study is a 24-week Induction and Maintenance Period and a 72-week
Long-Term Extension Period treat-through design study that utilizes a platform framework. The study will
evaluate the clinical efficacy and safety of targeted therapies (TaTs) in moderate to severe CD. For the purpose
of this protocol, TaTs represent biologic or biosimilar agents, and targeted small molecules that can be assessed
as monotherapies or combination therapies